Tom Bäck
YOU?
Author Swipe
View article: On-site activity determination of 211At using absolute 4pi-alpha liquid scintillation counting and HPGe
On-site activity determination of 211At using absolute 4pi-alpha liquid scintillation counting and HPGe Open
For accurate activity measurements and to comply with EU regulations traceability is required. For alpha emitters of interest for emerging targeted alpha therapies (TAT), like 211At, standardised samples are not readily available. The use …
View article: A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial
A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial Open
Astatine-211 is a nuclide with a short half-life of 7.2 h, that show promise for targeted alpha therapy of disseminated cancer. Despite nuclide production being straight-forward using a medium energy cyclotron and an uncomplicated target, …
View article: <sup>211</sup>At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation
<sup>211</sup>At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation Open
The α-emitter 211At deposits a high amount of energy within a few cell diameters, resulting in irreparable DNA double-strand breaks while minimizing off-target toxicity. We investigated the use of the 211At-labeled anti-CD45 monoclonal ant…
View article: A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells <i>In Vitro</i>
A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells <i>In Vitro</i> Open
Background: Real-time quantification of radioligand binding to cells under in vivo-like conditions improves evaluation of clinical potential. Materials and Methods: SKOV-3 tumor cells were grown in a monolayer on a thin glass plate placed …
View article: Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211
Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211 Open
To enhance targeting efficacy in the radioimmunotherapy of disseminated cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumor is pretargeted with a modified monoclonal antibody that has a…
View article: Supplementary Data, Supplementary Figures 1 and 2, Supplementary Tables 1-6 from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
Supplementary Data, Supplementary Figures 1 and 2, Supplementary Tables 1-6 from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow Open
Supplementary Figure S1. Estimating regional tumor volume within transverse sections. Table S1. Tumor dimensions of the human breast cancer cells inoculated into tibiae Supplementary Figure S2. Clonogenic survival of alpha-particle irradia…
View article: Data from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
Data from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow Open
Radiation-induced bystander effects have been implicated in contributing to the growth delay of disseminated tumor cells (DTC) caused by 223RaCl2, an alpha particle–emitting radiopharmaceutical. To understand how 223RaCl2 affects the growt…
View article: Data from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
Data from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow Open
Radiation-induced bystander effects have been implicated in contributing to the growth delay of disseminated tumor cells (DTC) caused by 223RaCl2, an alpha particle–emitting radiopharmaceutical. To understand how 223RaCl2 affects the growt…
View article: Supplementary Data, Supplementary Figures 1 and 2, Supplementary Tables 1-6 from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
Supplementary Data, Supplementary Figures 1 and 2, Supplementary Tables 1-6 from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow Open
Supplementary Figure S1. Estimating regional tumor volume within transverse sections. Table S1. Tumor dimensions of the human breast cancer cells inoculated into tibiae Supplementary Figure S2. Clonogenic survival of alpha-particle irradia…
View article: Astatine-211 based radionuclide therapy: Current clinical trial landscape
Astatine-211 based radionuclide therapy: Current clinical trial landscape Open
Astatine-211 ( 211 At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the mai…
View article: Estimating the Risk for Secondary Cancer After Targeted α-Therapy with<sup>211</sup>At Intraperitoneal Radioimmunotherapy
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with<sup>211</sup>At Intraperitoneal Radioimmunotherapy Open
Intraperitoneal 211At-based targeted α-therapy (TAT) may hold great promise as an adjuvant therapy after surgery and chemotherapy in epithelial ovarian cancer to eradicate any remaining undetectable disease. This implies that it will also …
View article: Covalent core-radiolabeling of polymeric micelles with <sup>125</sup>I/<sup>211</sup>At for theranostic radiotherapy
Covalent core-radiolabeling of polymeric micelles with <sup>125</sup>I/<sup>211</sup>At for theranostic radiotherapy Open
Astatine-211 (211At) is one of the most promising α-emitters for targeted alpha therapy, especially of cancer metastases. However, the lack of a stable isotope, frequent in vivo deastatination, and limited radiochemical knowledge makes it …
View article: Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy
Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy Open
Targeted α-therapy (TAT) can eradicate tumor metastases while limiting overall toxicity. One of the most promising α-particle emitters is astatine-211 (211At). However, 211At-carbon bonds are notoriously unstable in vivo and no chelators a…
View article: Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223
Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223 Open
This modeling study demonstrates that DE of radiation alone cannot explain experimental observations of 223RaCl2-induced growth delay of human breast cancer xenografts. Furthermore, while the mechanisms underlying BE remain unclear, the ad…
View article: Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow Open
Radiation-induced bystander effects have been implicated in contributing to the growth delay of disseminated tumor cells (DTC) caused by 223RaCl2, an alpha particle–emitting radiopharmaceutical. To understand how 223RaCl2 affects the growt…
View article: Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer Open
The current investigation of intraperitoneal therapy with 211At-farletuzumab, delivered at clinically relevant 211At-mAb radioactivity concentrations and specific activities, showed a 6 to 10-fold increase (treated versus controls) in anti…
View article: Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure Open
Despite the consensus around the clinical potential of the α-emitting radionuclide astatine-211 (211At), there are only a limited number of research facilities that work with this nuclide. There are three main reasons for this: (1) Scarce …
View article: Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors Open
Purpose Targeted alpha therapy (TAT) is a promising treatment for micrometastatic and minimal residual cancer. We evaluated systemic α-radioimmunotherapy (α-RIT) of metastatic castration-resistant prostate cancer (mCRPC) using the α-partic…
View article: Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with<sup>223</sup>Ra: The Role of Bystander Effects and Their Potential for Therapy
Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with<sup>223</sup>Ra: The Role of Bystander Effects and Their Potential for Therapy Open
The role of radiation-induced bystander effects in radiation therapy remains unclear. With renewed interest in therapy with α-particle emitters, and their potential for sterilizing disseminated tumor cells (DTCs), it is critical to determi…
View article: Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior
Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior Open
The use of nanobodies (Nbs) as vehicles in targeted alpha therapy (TAT) has gained great interest because of their excellent properties. They combine high in vivo affinity and specificity of binding with fast kinetics. This research invest…
View article: Intraperitoneal α-Emitting Radioimmunotherapy with<sup>211</sup>At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
Intraperitoneal α-Emitting Radioimmunotherapy with<sup>211</sup>At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations Open
Eliminating microscopic residual disease with α-particle radiation is theoretically appealing. After extensive preclinical work with α-particle-emitting 211At, we performed a phase I trial with intraperitoneal α-particle therapy in epithel…
View article: Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes
Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes Open
Intraperitoneally administered radiolabeled monoclonal antibodies (mAbs) have been tested in several clinical trials, often with promising results, but have never proven curative. Methods: We have previously presented simulations of clinic…